<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5548">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170882</url>
  </required_header>
  <id_info>
    <org_study_id>C16029</org_study_id>
    <secondary_id>2016-004742-28</secondary_id>
    <secondary_id>U1111-1188-2677</secondary_id>
    <secondary_id>2017/1235</secondary_id>
    <secondary_id>N-20170083</secondary_id>
    <secondary_id>17/NW/0546</secondary_id>
    <nct_id>NCT03170882</nct_id>
  </id_info>
  <brief_title>A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to learn if ixazomib, given with dexamethasone, stops the&#xD;
      cancer from getting worse in people with relapsed or refractory multiple myeloma. It will be&#xD;
      compared to another medicine called pomalidomide, given with dexamethasone with people with&#xD;
      the same condition. Relapsed means the previous cancer treatment stopped working, over time.&#xD;
      Refractory means they did not respond to previous cancer treatment. Another aim is to check&#xD;
      for side effects from the study medicines.&#xD;
&#xD;
      At the first visit, the study doctor will check who can take part. Participants who can take&#xD;
      part will be picked for 1 of 2 treatments by chance.&#xD;
&#xD;
        -  Ixazomib capsules, given with dexamethasone tablets&#xD;
&#xD;
        -  Pomalidomide capsules, given with dexamethasone tablets&#xD;
&#xD;
      All participants will take their study medicine on specific days during a 28-day cycle.&#xD;
&#xD;
      The 1st dose of study medicines in each 28-day cycle will take place in the clinic, The other&#xD;
      doses of the study medicines will be taken at home. This will happen for 6 cycles. After&#xD;
      this, all study medicines will be taken at home.&#xD;
&#xD;
      After treatment, participants will visit the clinic every 12 weeks for a check-up.&#xD;
&#xD;
      If participants cannot attend their clinic for an important reason (for example, due to the&#xD;
      COVID-19 pandemic), the clinic will make alternative arrangements using their local&#xD;
      procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat&#xD;
      people who have RRMM. This study will compare the efficacy and safety in participants who&#xD;
      take ixazomib and dexamethasone to pomalidomide and dexamethasone. It is an open-label, Phase&#xD;
      2 study.&#xD;
&#xD;
      The study will enroll approximately 120 participants. Participants will receive:&#xD;
&#xD;
        -  Ixazomib 4 mg + dexamethasone 20 mg (or 10 mg if participant is aged &gt;=75 years) OR&#xD;
&#xD;
        -  pomalidomide 4 mg + dexamethasone 40 mg (or 20 mg if participant is aged &gt;=75 years)&#xD;
&#xD;
      All participants will be asked to take either ixazomib plus dexamethasone (in cases where&#xD;
      only 4 mg tablets for dexamethasone are available, the following dexamethasone schedule is&#xD;
      recommended for participants aged &gt;=75 years: 12 mg dexamethasone will be given on Days 1, 8,&#xD;
      15, and 22 of every 28-day cycle; and 8 mg dexamethasone will be given on Days 2, 9, 16, and&#xD;
      23 of every 28-day cycle) or pomalidomide 4 mg + dexamethasone 40 mg at recommended doses.&#xD;
&#xD;
      This multi-center trial will be conducted worldwide. The overall time to participate in this&#xD;
      study is approximately 28 months after the first participant enters the study.&#xD;
&#xD;
      Participants will make multiple visits to the clinic, and will be contacted for PFS&#xD;
      follow-up, in case of study drug discontinuation for up to 4 years from first dose&#xD;
      administration. After disease progression, participants will be followed-up for OS every 12&#xD;
      weeks until death or up to 4 years.&#xD;
&#xD;
      Alternative methods for administering study procedures/assessments may be considered when it&#xD;
      is not possible for the participants to come to the study site due to extenuating&#xD;
      circumstances (e.g., due to the COVID-19 pandemic).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">June 16, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of randomization until first occurrence of confirmed disease progression or death due to any cause, whichever occurs first (Up to 4 years)</time_frame>
    <description>PFS: Time from randomization to first occurrence of confirmed progressive disease (PD) as assessed by investigator by International Myeloma Working Group(IMWG) response criteria/death from any cause, whichever occurs first. PD requires following: Increase of greater than or equal to (&gt;=) 25percent (%) from nadir in: Serum M component (increase must be &gt;=0.5 gram per deciliter [g/dl]); Urine M-component (increase must be &gt;=200 milligram [mg]/24-hour); In participants without measurable serum and urine M-protein levels difference between involved and uninvolved free light chain (FLC) increase of greater than (&gt;) 10 mg/dl; In participants without measurable serum and urine M protein levels and without measurable disease by FLC level: bone marrow plasma cell percentage must be &gt;=10%; Development of new/increase in size of existing bone lesions/soft tissue plasmacytomas; development of hypercalcemia(&gt;11.5mg/dL corrected serum calcium)attributed solely to plasma cell proliferative disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization to death from any cause (Up to 4 years)</time_frame>
    <description>OS is defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Objective Response Rate (ORR)</measure>
    <time_frame>Day 1 of Cycle 1 (28 day cycle) then every cycle until disease progression for up to 4 years</time_frame>
    <description>ORR is defined as the percentage of participants who achieve partial response (PR), very good partial response (VGPR), or complete response (CR) based on laboratory results and IRC assessment using modified IMWG criteria. PR: &gt;=50% reduction of serum M protein + reduction in 24-hour urinary M protein by &gt;=90% or to &lt;200 mg/24-hour; if M protein is not measurable, &gt;=50% decrease in difference between involved and uninvolved FLC levels is required; if not measurable by FLC, &gt;=50% reduction in bone marrow plasma cells, when baseline value &gt;=30% and; if present at baseline, &gt;=50% reduction in size of soft tissue plasmacytomas is required; VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;=90% reduction in serum M-protein + urine M-protein level &lt;100 mg/24-hour. CR: negative immunofixation on serum + urine; disappearance of soft tissue plasmacytomas; less than (&lt;)5% plasma cells in bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Day 1 of Cycle 1 (28 day cycle) then every cycle until disease progression for up to 4 years</time_frame>
    <description>DOR: Time from first documentation of CR/PR/VGPR to first documentation of PD. Per IMWG criteria, PR:&gt;=50% reduction of serum M protein+reduction in 24-hour urinary M protein by &gt;=90% to &lt;200 mg/24-hour or &gt;=50% decrease in difference between involved and uninvolved FLC levels/ &gt;=50% reduction in bone marrow plasma cells, if &gt;=30% at baseline/ &gt;=50% reduction in size of soft tissue plasmacytomas. VGPR: serum+urine M-protein detectable by immunofixation but not on electrophoresis/ &gt;=90% reduction in serum M-protein + urine M-protein level &lt;100 mg/24-hour. CR:negative immunofixation on serum + urine+disappearance of soft tissue plasmacytomas+&lt;5% plasma cells in bone marrow. PD:serum M-component increase &gt;=0.5 g/dl or urine M-component increase &gt;=200 mg/24-hour/ difference between involved and uninvolved FLC levels increase &gt;10 mg/dl or bone marrow plasma cell &gt;=10%/development of new/ increase in size of existing bone lesions or soft tissue plasmacytoma or development of hypercalcemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Day 1 of Cycle 1 (28 day cycle) then every cycle until the first documentation of PR or PR/VGPR/CR for up to 4 years</time_frame>
    <description>Time to response is defined as the time from randomization to the first documentation of PR/VGPR/CR. Per IMWG criteria PR is defined as &gt;=50% reduction of serum M protein + reduction in 24-hour urinary M protein by &gt;=90% or to &lt;200 mg/24-hour; if M-protein is not measurable, &gt;=50% decrease in difference between involved and uninvolved FLC levels is required; if not measurable by FLC, &gt;=50% reduction in bone marrow plasma cells, when baseline value &gt;=30% and; if present at baseline, &gt;=50% reduction in size of soft tissue plasmacytomas is required; VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;=90% reduction in serum M-protein + urine M-protein level &lt;100 mg/24-hour. CR: negative immunofixation on serum + urine; disappearance of soft tissue plasmacytomas; &lt;5% plasma cells in bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Day 1 of Cycle 1 (28 day cycle) then every cycle until disease progression for up to 4 years</time_frame>
    <description>TTP is defined as the time from randomization to first documentation of PD. Per IMWG criteria, PD requires 1 of the following: Increase of &gt;=25% from nadir in: Serum M-component (increase must be &gt;=0.5 g/dl; Urine M-component (increase must be &gt;=200 mg/24-hour); In participants without measurable serum and urine M-protein levels difference between involved and uninvolved FLC levels increase of &gt;10 mg/dl; In participants without measurable serum and urine M protein levels and without measurable disease by FLC level: Bone marrow plasma cell percentage must be &gt;=10%; Development of new or increase in size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (&gt;11.5 mg/dL corrected serum calcium) attributed solely to plasma cell proliferative disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQOL) Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30 (EORTC QLQ-C30) Physical Domain Score</measure>
    <time_frame>Baseline up to 4 years</time_frame>
    <description>The EORTC QLQ-C30 physical domain consists of 5 items covering participant's daily physical activities. The total score reported is between 0 and 100, with a high score indicating better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL Based on EORTC QLQ-C30 Total Score</measure>
    <time_frame>Baseline up to 4 years</time_frame>
    <description>The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/quality of life (QOL) scale. Most of the 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL Based on EORTC Multiple Myeloma Module 20 (EORTC QLQ-MY20) Score</measure>
    <time_frame>Baseline up to 4 years</time_frame>
    <description>The EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms, and side effects of treatment). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score is equal to (=) better perspective of the future. For the body image scale, higher scores = better body image. Higher score for the disease symptoms scale = higher level of symptomatology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL Based on 5-level Classification System of the EuroQol 5-Dimensional Health Questionnaire (EQ-5D-5L) Score</measure>
    <time_frame>Baseline up to 4 years</time_frame>
    <description>The EQ-5D-5L consists of 2 domains: the EQ-5D-5L descriptive system and the EuroQol visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on 5 levels. 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extremely severe problems. The EQ VAS records the respondent's self-rated health on a 20 centimeter (cm), vertical, visual analogue scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The scores from all dimensions are combined into a single index score that is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Utilization (HU): Number of Medical Encounters</measure>
    <time_frame>Baseline up to 4 years</time_frame>
    <description>HU as measured by the number of medical encounters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HU: Duration of Medical Encounters</measure>
    <time_frame>Baseline up to 4 years</time_frame>
    <description>HU as measured by the duration of medical encounters.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Relapsed and/or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Ixazomib plus dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib 4 mg as starting dose, capsules, orally on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at Cycle 2 for participants who tolerate the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged &gt;=75 years) tablets, orally, on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study (Up to 28 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide plus dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pomalidomide 4 mg, capsules, orally on Days 1 to 21 of each 28-day cycle, plus dexamethasone 40 mg, (or 20 mg if participant is aged &gt;=75 years), tablets, orally on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study (Up to 28 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <description>Ixazomib capsules.</description>
    <arm_group_label>Ixazomib plus dexamethasone</arm_group_label>
    <other_name>NINLARO</other_name>
    <other_name>MLN9708</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide capsules.</description>
    <arm_group_label>Pomalidomide plus dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone tablets.</description>
    <arm_group_label>Ixazomib plus dexamethasone</arm_group_label>
    <arm_group_label>Pomalidomide plus dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have a confirmed diagnosis of multiple myeloma (MM) requiring therapy according&#xD;
             to IMWG criteria.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          3. Must have had a relapse or PD after having received 2 or more prior lines of systemic&#xD;
             therapy. Note: A line of therapy is defined as 1 or more cycles of a planned treatment&#xD;
             program; this may consist of 1 or more planned cycles of single-agent therapy or&#xD;
             combination therapy, as well as a sequence of treatments administered in a planned&#xD;
             manner. For example, a planned treatment approach of induction therapy followed by&#xD;
             autologous SCT, followed by maintenance is considered 1 line of therapy. Typically&#xD;
             each line of therapy is separated by PD. Discussion with the medical monitor may help&#xD;
             clarify the number of lines of therapy that a prospective study participant had.&#xD;
&#xD;
          4. Must be refractory to lenalidomide, defined as having received at least 2 consecutive&#xD;
             cycles of lenalidomide as a single agent or within a lenalidomide-containing regimen&#xD;
             and having had PD during treatment with or within 60 days after the last dose of&#xD;
             lenalidomide. The starting dose of lenalidomide should have been 25 mg (or as low as&#xD;
             10 mg in the case of renal function impairment or other safety concern), and the final&#xD;
             dose should have been a minimum of 10 mg.&#xD;
&#xD;
          5. Must have received at least 2 consecutive cycles of a bortezomib- or&#xD;
             carfilzomib-containing regimen, and either:&#xD;
&#xD;
               -  Achieved at least a PR and did not have PD during treatment with or within 60&#xD;
                  days after the last dose of bortezomib or carfilzomib, OR&#xD;
&#xD;
               -  Had bortezomib and/or carfilzomib intolerance (defined as discontinuation because&#xD;
                  of drug-related adverse events [AEs] before completion of the planned treatment&#xD;
                  course) without PD before the start of the next regimen.&#xD;
&#xD;
          6. Must have measurable disease defined by:&#xD;
&#xD;
               -  Serum M-protein &gt;=1 g/dL (&gt;=10 g/L), OR&#xD;
&#xD;
               -  Urine M-protein &gt;=200 mg/24 hours and must have documented MM isotype by&#xD;
                  immunofixation (central laboratory).&#xD;
&#xD;
          7. Suitable venous access for the study-required blood sampling, including&#xD;
             pharmacokinetic (PK) sampling.&#xD;
&#xD;
          8. Recovered (that is, less than or equal to [&lt;=] Grade 1 nonhematologic toxicity) from&#xD;
             the reversible effects of prior anticancer therapy.&#xD;
&#xD;
          9. Must be willing and able to adhere to pomalidomide-related risk mitigation activities&#xD;
             if randomized to the pom+dex arm (example, Risk Evaluation and Mitigation Strategies&#xD;
             [REMS], pregnancy prevention programs).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior allogenic bone marrow transplantation in any prior line of therapy or prior&#xD;
             autologous SCT in the last prior line of therapy- unless the autologous SCT was&#xD;
             performed a year or more before disease progression.&#xD;
&#xD;
          2. Diagnosed with or treated for another malignancy within 2 years before randomization,&#xD;
             or previously diagnosed with another malignancy and have any evidence of residual,&#xD;
             persistent, or recurrent disease. Participants with nonmelanoma skin cancer or&#xD;
             carcinoma in situ of any type are not excluded if they have undergone complete&#xD;
             resection.&#xD;
&#xD;
          3. Diagnosis of smoldering MM, Waldenstr√∂m's macroglobulinemia, POEMS (polyneuropathy,&#xD;
             organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome,&#xD;
             plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or&#xD;
             myeloproliferative syndrome.&#xD;
&#xD;
          4. Peripheral neuropathy Grade 1 with pain or Grade 2 or higher peripheral neuropathy of&#xD;
             any cause on clinical examination during the Screening period.&#xD;
&#xD;
          5. Treatment with any investigational products or with chimeric or fully human monoclonal&#xD;
             antibodies within 30 days before randomization, systemic anticancer therapy or&#xD;
             radiotherapy within 14 days before randomization (Note: &quot;spot&quot; radiation for areas of&#xD;
             pain is permitted), and major surgery within 14 days before randomization.&#xD;
&#xD;
          6. Known gastrointestinal disease or gastrointestinal procedure that could interfere with&#xD;
             the oral absorption or tolerance of study therapy, including difficulty swallowing.&#xD;
&#xD;
          7. Serious infection requiring parenteral antibiotic therapy or any other serious&#xD;
             infection within 14 days before randomization.&#xD;
&#xD;
          8. Central nervous system involvement with MM (by clinical symptoms and signs).&#xD;
&#xD;
          9. Ongoing or active systemic infection, known human immunodeficiency virus-ribonucleic&#xD;
             acid (RNA) positive, known hepatitis B surface antigen seropositive, or known&#xD;
             hepatitis C virus-RNA positive.&#xD;
&#xD;
         10. Systemic treatment with strong cytochrome P-450 3A inducers (rifampin, rifapentine,&#xD;
             rifabutin, carbamazepine, phenytoin, phenobarbital) or use of St. John's wort within&#xD;
             14 days before randomization.&#xD;
&#xD;
         11. Admission or evidence of illicit drug use, drug abuse, or alcohol abuse.&#xD;
&#xD;
         12. History of severe cutaneous reactions, including hypersensitivity reactions such as&#xD;
             Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction&#xD;
             with Eosinophilia and Systemic Symptoms (DRESS), in the context of treatment with&#xD;
             lenalidomide or thalidomide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Cancer Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan Oncology Associates</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Care South Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen</name>
      <address>
        <city>Wilrijk</city>
        <state>Antwerpen</state>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St Jan Brugge Oostende AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Center</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <state>Kralovehradeck Kraj</state>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <state>Olomouck Kraj</state>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <state>Praha, Hlavni Mesto</state>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha</city>
        <state>Praha, Hlavni Mesto</state>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Plzen</name>
      <address>
        <city>Plzen Lochotin</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Universitetshospital</name>
      <address>
        <city>Aalborg</city>
        <state>Nordjylland</state>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne Centre Regional de Lutte Contre Le Cancer</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Dijon Complexe Du Bocage</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d'Or</state>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - Hopital Morvan</name>
      <address>
        <city>Brest</city>
        <state>Finistere</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Atlantique Vannes</name>
      <address>
        <city>Vannes</city>
        <state>Morbihan</state>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans</name>
      <address>
        <city>Le Mans</city>
        <state>Sarthe</state>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier du Havre</name>
      <address>
        <city>Montivilliers</city>
        <state>Seine-Maritime</state>
        <zip>76290</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hopital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Fleyriat</name>
      <address>
        <city>Bourg-en- Bresse Cedex</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier (CH) William Morey</name>
      <address>
        <city>Chalon sur Saone</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital d Instructions des Armees Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard Clinique Victor Hugo</name>
      <address>
        <city>Le Mans cedex 2</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional d'Orleans</name>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Perigueux</name>
      <address>
        <city>Perigueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Poitiers La Miletrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Rennes</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uberortliche Gemeinschaftspraxis Pasing und Furstenfeldbruck</name>
      <address>
        <city>Munchen</city>
        <state>Bayern</state>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Dusseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Alexandroupolis</name>
      <address>
        <city>Alexandroupoli</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelismos General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theageneio Anticancer Oncology Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54007</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Centre</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Corporation</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Davis Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Delle Croci</name>
      <address>
        <city>Ravenna</city>
        <state>Emilia-Romagna</state>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infermi di Rimini</name>
      <address>
        <city>Rimini</city>
        <state>Emilia-Romagna</state>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Marche Nord</name>
      <address>
        <city>Pesaro</city>
        <state>Marche</state>
        <zip>61122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per lOncologia (IRCCS)</name>
      <address>
        <city>Candiolo</city>
        <state>Piemonte</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera S Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Piemonte</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Citta della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Di Riferimento Oncologico Della Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>PZ</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Di Modena Policlinico</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Della Misericordia</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ULSS 6 Vicenza</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <state>Zuid-Holland</state>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Sittard</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <state>Oppland</state>
        <zip>N-1346</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <zip>N-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forde Sentralsjukehus</name>
      <address>
        <city>Forde</city>
        <zip>6812</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger Universitetssykehus</name>
      <address>
        <city>Stavanger</city>
        <zip>N-4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>N-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirov Research Institute of Haematology and Blood Transfusion</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Scientific Center</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital n a S P Botkin</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 40</name>
      <address>
        <city>Moscow</city>
        <zip>129301</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara State Medical University</name>
      <address>
        <city>Samara</city>
        <zip>433021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Communidad Delaware</state>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Dr Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborg Lasarett</name>
      <address>
        <city>Helsingborg</city>
        <state>Skane Lan</state>
        <zip>SE-25187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sodra Alvsborgs Sjukhus Boras</name>
      <address>
        <city>Boras</city>
        <zip>SE-50182</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty Gazi Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical Faculty Cebeci Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erciyes Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Betsi Cadwaladr University Health Board</name>
      <address>
        <city>Bodelwyddan</city>
        <state>Denbighshire-SirDdinbych</state>
        <zip>LL18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>Dorset</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kent and Canterbury Hospital</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare Oxford</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX4 6LB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke-on-Trent</city>
        <state>Staffordshire</state>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b60204db2bf003ab49572</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

